Call for action: incorporating wellness practices into a holistic management plan for rheumatoid arthritis-going beyond treat to target.

autoimmune diseases patient care team physical therapy modalities rheumatoid arthritis

Journal

RMD open
ISSN: 2056-5933
Titre abrégé: RMD Open
Pays: England
ID NLM: 101662038

Informations de publication

Date de publication:
12 2021
Historique:
received: 22 09 2021
accepted: 23 11 2021
entrez: 11 12 2021
pubmed: 12 12 2021
medline: 5 1 2022
Statut: ppublish

Résumé

This expert opinion article explores the strategy of adopting a holistic approach to the management of rheumatoid arthritis (RA) by incorporating the wellness practices of exercise, optimised sleep, optimised nutrition, mindfulness, social connectedness and positive emotions into the management plan. The aim is to attain optimal health for each patient beyond that achievable by limiting disease management to pharmacological treatment to attain the lowest achievable composite scores of disease activity, as recommended with the current treat-to-target approach, and addressing the recent recognition of pain control as a key patient-reported outcome. Incorporating wellness practices into a busy clinical setting requires creativity and customisation based on the individual practice setting and the individual needs of each patient. Such practices can help people living with RA to achieve optimum wellness through the introduction of measures-according to individual need-designed to improve the aspects of life most impacted for that person, thereby complementing treat-to-target and pain control strategies with pharmacological agents. Clinicians must consider wellness practices in addition to treat-to-target pharmacological agents for the holistic management of people with RA.

Identifiants

pubmed: 34893537
pii: rmdopen-2021-001959
doi: 10.1136/rmdopen-2021-001959
pmc: PMC8666892
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: PT: Research grants from Celgene and Galapagos and consultation fees from AbbVie, Biogen, Galapagos, Gilead, GlaxoSmithKline, Janssen, Lilly, Pfizer, BMS, Roche, Sanofi, Nordic Pharma, Fresenius and UCB. SJ has served as a consultant, member of advisory boards and/or speaker bureaus for Eli Lilly, Otsuka, Pamlab and Sunovion. MVdL reports educational grants and speaker’s–advisory fees from Eli Lilly and Company not related to this work. AL has been member of speaker bureaus for Lilly, Novartis, Amgen, Exage, Myria and Pfizer and a consultant for Amgen. WF, AQ and IdlT are employees of Eli Lilly and Company.

Références

Clin Exp Rheumatol. 2008 Sep-Oct;26(5 Suppl 51):S14-20
pubmed: 19026141
Curr Rheumatol Rep. 2017 Nov 9;19(12):80
pubmed: 29119260
Front Hum Neurosci. 2017 Jun 20;11:316
pubmed: 28676747
Ann Rheum Dis. 2020 Jun;79(6):685-699
pubmed: 31969328
Neuropsychopharmacology. 2017 Jan;42(1):129-155
pubmed: 27510422
Complement Ther Clin Pract. 2019 Feb;34:139-144
pubmed: 30712718
Am J Lifestyle Med. 2015 Oct 07;11(6):466-475
pubmed: 30202372
Cochrane Database Syst Rev. 2009 Oct 07;(4):CD006853
pubmed: 19821388
RMD Open. 2020 Apr;6(1):
pubmed: 32371431
Sports Med. 2015 Oct;45(10):1401-12
pubmed: 26219268
Contemp Clin Trials Commun. 2020 Jan 21;17:100524
pubmed: 32025586
BMC Fam Pract. 2018 Jan 8;19(1):6
pubmed: 29310572
J Rheumatol. 2014 Oct;41(10):1966-73
pubmed: 25128510
Neurosci Biobehav Rev. 2006;30(2):173-87
pubmed: 16099508
Obes Res Clin Pract. 2014 Mar-Apr;8(2):e131-9
pubmed: 24743008
Neurosci Lett. 2013 Oct 11;553:201-5
pubmed: 23988308
Disabil Health J. 2010 Jul;3(3):133-45
pubmed: 20628583
Ann Rheum Dis. 2015 Feb;74(2):472-4
pubmed: 25406303
Ann Rheum Dis. 2010 Oct;69(10):1768-73
pubmed: 20610444
Sleep Med Clin. 2018 Jun;13(2):147-159
pubmed: 29759266
Physiol Rev. 2019 Jul 1;99(3):1325-1380
pubmed: 30920354
Arthritis Care Res (Hoboken). 2014 Feb;66(2):217-27
pubmed: 23925924
Acta Reumatol Port. 2021 Jan-Mar;46(1):40-54
pubmed: 33820895
Int J Nurs Stud. 2015 Oct;52(10):1617-24
pubmed: 26117711
Ann Rheum Dis. 2012 Jun;71(6):911-7
pubmed: 22186709
Ann Behav Med. 2010 Oct;40(2):218-27
pubmed: 20652462
RMD Open. 2021 May;7(2):
pubmed: 34049997
Acta Reumatol Port. 2019 Apr 22;44(2):132-137
pubmed: 31235679
Ann Rheum Dis. 2017 Aug;76(8):1357-1364
pubmed: 28137914
Health Soc Care Community. 2015 Sep;23(5):467-84
pubmed: 25494621
J Clin Sleep Med. 2011 Feb 15;7(1):49-55
pubmed: 21344040
Sleep. 2012 Apr 01;35(4):537-43
pubmed: 22467992
Sleep. 2015 Nov 01;38(11):1751-64
pubmed: 25902806
Psychosom Med. 2016 Jun;78(5):532-41
pubmed: 26867077
Biodemography Soc Biol. 2014;60(1):21-37
pubmed: 24784985
J Pain. 2010 Mar;11(3):199-209
pubmed: 19853530
Clin Exp Rheumatol. 2012 Nov-Dec;30(6):899-904
pubmed: 22992291
Lancet. 2016 Oct 22;388(10055):2023-2038
pubmed: 27156434
Emotion. 2015 Apr;15(2):129-33
pubmed: 25603133
Br J Nutr. 2012 Jun;107 Suppl 2:S171-84
pubmed: 22591891
Clin Rheumatol. 2009 Jun;28(6):663-71
pubmed: 19247575
Psychol Sci. 2013 Jul 1;24(7):1123-32
pubmed: 23649562
J Rheumatol. 2006 Oct;33(10):1942-51
pubmed: 16960928
Ann Rheum Dis. 2011 Jun;70(6):1060-7
pubmed: 21540202
Soc Neurosci. 2017 Jun;12(3):242-252
pubmed: 27072369
Sleep Med Rev. 2015 Aug;22:23-36
pubmed: 25454674
Neurosci Biobehav Rev. 2015 Aug;55:68-77
pubmed: 25956251
J Aging Res. 2011 Feb 13;2011:681640
pubmed: 21403833
J Rheumatol. 2003 Apr;30(4):868-72
pubmed: 12672218
Ann Rheum Dis. 2021 Oct;80(10):1278-1285
pubmed: 33962964
Arthritis Rheumatol. 2021 Jul;73(7):1108-1123
pubmed: 34101376
Neuro Endocrinol Lett. 2011;32(4):458-63
pubmed: 21876513
Ann Rheum Dis. 2009 Nov;68(11):1680-5
pubmed: 19054825
J Prim Care Community Health. 2017 Oct;8(4):239-246
pubmed: 28643551
Rheumatol Int. 2018 Jun;38(6):935-947
pubmed: 29564549
J Clin Med. 2018 Oct 09;7(10):
pubmed: 30304765
J Neurosci. 2015 Nov 18;35(46):15307-25
pubmed: 26586819
Health Qual Life Outcomes. 2008 Jul 24;6:54
pubmed: 18651986
Rheumatol Ther. 2019 Dec;6(4):587-597
pubmed: 31659680
Psychiatry Res. 2011 Jan 30;191(1):36-43
pubmed: 21071182
Conscious Cogn. 2017 May;51:157-165
pubmed: 28376373
Rheumatology (Oxford). 2000 Nov;39(11):1287-9
pubmed: 11085813
Br J Gen Pract. 2014 Jul;64(624):368-9
pubmed: 24982488
Sports Med. 2013 Apr;43(4):243-56
pubmed: 23494259
Arthritis Res Ther. 2018 Aug 9;20(1):175
pubmed: 30092814
Am J Clin Nutr. 2020 Jun 1;111(6):1203-1213
pubmed: 32055820
Ann Rheum Dis. 2003 Mar;62(3):208-14
pubmed: 12594104
Am Heart J. 2013 Oct;166(4):622-628.e1
pubmed: 24093840
Games Health J. 2020 Oct;9(5):368-375
pubmed: 32315553
Transl Behav Med. 2016 Mar;6(1):63-72
pubmed: 27012254
Cells. 2020 Mar 30;9(4):
pubmed: 32235564
J Sleep Res. 2014 Apr;23(2):124-32
pubmed: 24635564

Auteurs

Peter C Taylor (PC)

Botnar Research Centre, NDORMS, University of Oxford, Oxford, UK peter.taylor@kennedy.ox.ac.uk.

Mart Van de Laar (M)

Transparency in Healthcare B.V, University of Twente, Hengelo, The Netherlands.

Andrew Laster (A)

Arthritis & Osteoporosis Consultants of the Carolinas, Charlotte, North Carolina, USA.

Walid Fakhouri (W)

Eli Lilly and Company, Indianapolis, Indiana, USA.

Amanda Quebe (A)

Eli Lilly and Company, Indianapolis, Indiana, USA.

Inmaculada de la Torre (I)

Eli Lilly and Company, Indianapolis, Indiana, USA.

Saundra Jain (S)

School of Nursing, The University of Texas at Austin, Austin, Texas, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH